Abstract: Peptides have immune system modulation properties. The immunologically active peptides can be derived from the heavy-chain complementarity determining region-3 of a humanized monoclonal antibody to NaPi2B transporter. Such peptides can be used to modulate the immune system of a subject under cancer treatment.
Abstract: The present disclosure identifies pathways, mechanisms, systems and methods to confer production of carbon-based products of interest, such as sugars, alcohols, chemicals, amino acids, polymers, fatty acids and their derivatives, hydrocarbons, isoprenoids, and intermediates thereof, in engineered and/or evolved methylotrophs such that these organisms efficiently convert C1 compounds, such as formate, formic acid, formaldehyde or methanol, to organic carbon-based products of interest, and in particular the use of organisms for the commercial production of various carbon-based products of interest.
Abstract: The invention relates to (dried) capsules with a high active-ingredient or active-substance content, to the use of the capsules in cosmetic and/or pharmaceutical compositions and to the production of the capsules.
Abstract: The present invention relates to a polypeptide comprising a mutant fragment of an outer surface protein A (OspA), a nucleic acid coding the same, a pharmaceutical composition (particularly for use as a medicament of in a method of treating or preventing a Borrelia infection) comprising the polypeptide and/or the nucleic acid, a method of treating or preventing a Borrelia infection and a method of immunizing a subject.
Type:
Grant
Filed:
December 4, 2019
Date of Patent:
October 11, 2022
Assignee:
Valneva Austria GmbH
Inventors:
Pär Comstedt, Urban Lundberg, Andreas Meinke, Markus Hanner, Wolfgang Schüler, Benjamin Wizel, Christoph Reinisch, Brigitte Grohmann, Robert Schlegl
Abstract: Oral medicament comprising an osmotic laxative incorporated into a matrix based on plant fats. The present invention relates to an oral pharmaceutical composition comprising: between 30 and 55% by weight of said pharmaceutical composition of micronized anhydrous macrogol; and between 45 and 70% by weight of the pharmaceutical composition of a carrier consisting of an anhydrous hydrophobic lipid coating based on fatty compounds of plant origin, having a melting point of between 36 and 38° C., and to the use thereof as laxative. Said composition enables the reduction in the daily dosage of macrogol by preserving the osmotic pressure thereof as far as the colon, the site of therapeutic action of osmotic laxatives; said carrier protects the macrogol from a reduction, due to the moisture in the digestive tract, in the osmotic pressure.
Abstract: Provided herein are water soluble solid form compositions including a curcuminoid; and a solubilizer selected from one or more of methylsulfonylmethane (MSM) and steviol glycoside; glycerol polyethylene glycol hydroxystearate (GPGH) and steviol glycoside; fatty acid glycerol polyglycoester (GPE); steviol glycoside and an aromatic amino acid; and steviol glycoside. Also provided herein are methods of making the water soluble solid form compositions.
Abstract: The present invention relates to novel semi-synthetic meningococcal conjugate vaccine comprising novel synthetic oligosaccharide conjugated to a carrier protein. The present invention also relates to novel synthetic meningococcal oligosaccharide and a process for its preparation.
Abstract: A biodegradable and biocompatible three dimensional construct comprising a combination of a nano silicate (e.g., laponite) and two different polymers, the two polymers each individually providing at least one covalently linked polymer chain and at least one ionically linked polymer chain, the polymeric chains forming a dual strengthening intertwined polymeric system. The constructs demonstrate improved mechanical and strength properties, while the bioinks provide a material having superior printability characteristics suitable for printing a three dimensional biodegradable construct having an aspect ratio of greater than 2.0. The bioink may also comprise cells or combinations of cells. Methods of using the constructs and bioinks for wound healing preparations and tissue regeneration are also provided.
Abstract: The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
Type:
Grant
Filed:
January 31, 2020
Date of Patent:
August 16, 2022
Assignee:
FERRING B.V.
Inventors:
Salah U. Ahmed, Jiaxiang Tsao, Anu Mahashabde, Diane D. Harrison
Abstract: The present invention relates to a process for stripping keratin fibres, and in particular human keratin fibres such as the hair, dyed with oxidation dyes and/or direct dyes, using a composition obtained by extemporaneous mixing of an anhydrous or aqueous composition (A) comprising at least one suitably selected sulfinic acid derivative and an aqueous composition (B) with a pH of less than (5), comprising at least one organic acid other than the compounds of formula (I), with a pKa of less than or equal to (4) when the composition (A) is aqueous, the pH of the mixture of the two compositions (A) and (B) being less than or equal to (5). The invention also relates to a composition for stripping the artificial colour from keratin fibres, comprising at least one suitably selected sulfinic acid derivative and at least one thickener chosen from anionic polymers and nonionic polymers.
Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, an immunogenic composition for infants is provided comprising a multivalent Streptococcus pneumoniae vaccine comprising 2 or more capsular saccharide conjugates from different serotypes, wherein the composition comprises a serotype 22F saccharide conjugate. Such a vaccine may be used in infant populations to reduce the incidence of elderly pneumococcal disease such as exacerbations of COPD and/or IPD.
Type:
Grant
Filed:
January 12, 2018
Date of Patent:
August 2, 2022
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
Abstract: The aspects presented herein provide methods and compositions for the reduction of the peroxide value of perfume ingredients, formulated perfumes, formulated body care products, formulated skin care products, formulated homecare products, essential oils, food raw materials, formulated food products, and natural extracts.
Abstract: Disclosed herein are Mycoplasma bovis immunogenic compositions useful in raising an immune response in animals against M. bovis. Also disclosed herein are methods for generating a protective response against infections in mammals caused by M. bovis.
Type:
Grant
Filed:
August 11, 2016
Date of Patent:
July 19, 2022
Assignees:
Zoetis Services LLC
Inventors:
Glenn Francis Browning, Philip Francis Markham, Marc Serge Marenda, Fred H. Weber, Suman Mahan
Abstract: Some HBL and NHE enterotoxins are known to cause food-borne diseases in humans. Enterotoxin-deficient mutants of member strains of the Bacillus cereus group that do not produce HBL, HBLa1, HBLa2, or NHE enterotoxins are disclosed. Enterotoxin-deficient mutants are suitable for use as biocontrol agents. Methods for making the mutants and for using the mutants are described.
Type:
Grant
Filed:
June 11, 2018
Date of Patent:
July 5, 2022
Assignee:
WISCONSIN ALUMNI RESEARCH FOUNDATION
Inventors:
Jo Emily Handelsman, Amy Klimowicz, Changhui Guan
Abstract: The invention provides a T cell wherein one or more therapeutic transgenes is integrated at a within the genome of the cell such that expression of the transgene is under control of an endogenous promoter of the T cell. The invention additional provides methods of making and using such cells to treat a subject with T cell therapy. The invention also provides a T cell wherein a recombinant nucleic acid sequence encoding a chimeric antigen receptor (CAR) is integrated at a first site within the genome of the cell such that the CAR is expressed by the cell at the surface of the cell, and wherein integration of the nucleic acid encoding the CAR at the first site reduces or prevents expression of a functional T cell receptor (TCR) complex at the surface of the cell. The invention additional provides methods of making and using such cells to treat a subject with CAR therapy.
Type:
Grant
Filed:
April 14, 2017
Date of Patent:
July 5, 2022
Assignee:
Memorial Sloan Kettering Cancer Center
Inventors:
Michel W. J. Sadelain, Justin Gabriel Andre Francois Eyquem, Jorge Mansilla-Soto
Abstract: The present invention provides improved methods for producing a solution containing high molecular weight isolated Streptococcus pneumoniae capsular polysaccharides having phosphodiester linkages between saccharide repeat units. In certain methods, CO2 is supplied to a fermentation culture of Streptococcus pneumoniae bacterial cells that produce capsular polysaccharide serotypes containing phosphodiester linkages between saccharide repeat units. Exemplary Streptococcus pneumoniae serotypes containing a phosphodiester linkage between saccharide repeat units include serotypes 6A, 6B, 19A, and 19F. Supplying CO2 to the fermentation culture includes adding bicarbonate ions to the fermentation culture, adding carbonate ions to the fermentation culture, adding mixtures of bicarbonate and carbonate ions to the fermentation culture, and overlaying the fermentation culture with CO2.
Abstract: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target killed bacterial cells to specific mammalian cells and to cause endocytosis of the killed bacterial cells by the mammalian cells. Alternatively, the delivery method exploits the natural ability of phagocytic mammalian cells to engulf killed bacterial cells without the use of bispecific ligands.
Type:
Grant
Filed:
January 28, 2018
Date of Patent:
June 14, 2022
Assignee:
EngeneIC Molecular Delivery Pty Ltd
Inventors:
Himanshu Brahmbhatt, Jennifer MacDiarmid
Abstract: The present disclosure relates to protein molecules that specifically bind to CD3, which may have at least one humanized CD3-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to CD3 may have a second binding domain that binds to another target. In one embodiment, multispecific polypeptide molecules bind both tumor antigen-expressing cells and the CD3 subunit of a T-cell receptor complex on T-cells to induce target-dependent T-cell cytotoxicity, activation, and proliferation. The disclosure also provides pharmaceutical compositions comprising the CD3-binding poypeptide molecules, nucleic acid molecules encoding these polypeptides and methods of making these molecules.
Abstract: Disclosed are controlled release particles including: (a) a core including at least one vitamin which is oil-soluble or oil-dispersible; and (b) a wall at least partially surrounding the core, wherein the controlled release particles are produced by reacting (i) a first composition including a hydrophobic oil, the at least one vitamin, an anti-oxidant and a wax with (ii) a second composition including a water soluble emulsifier, a corn protein and a solvent to form an intermediate product, which is mixed with (iii) a third composition including a cellulosic polymer in water, and dehydrated to provide the controlled release particles. A method for preparing the particles and compositions containing the particles are also disclosed.
Abstract: Hyperblebbing Shigella strains are generated by disrupting one or more components of the Tol-Pal system. The blebs from these strains are useful immunogens for vaccination. The individual proteins found in these blebs can also be used as immunogens.
Type:
Grant
Filed:
April 8, 2016
Date of Patent:
May 24, 2022
Assignee:
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors:
Christiane Gerke, Francesco Berlanda Scorza, Allan Saul, Luana Maggiore